



# NeuroInvestment Index

NeuroInvestment is the premiere monthly review of the neurotherapeutics industry. This index lists the main therapeutic area covered in each issue, and some of the companies whose programs are covered in detail.

DATE	TOPIC	COMPANIES INCLUDED
<b>2010</b>		
January	<b>Review of 2009</b>	Preview of 2010/ <i>Spotlight: Probiodrug</i>
February	<b>Traumatic Brain Injury*</b>	KeyNeurotek, Neuren, others/ <i>Spotlight: KeyNeurotek</i>
<b>2009</b>		
January	<b>Review of 2008</b>	Preview of 2009/ <i>Spotlight: Synosia Therapeutics</i>
February	<b>Schizophrenia</b>	Merck, Lilly, Targacept, others/ <i>Spotlight: Catalyst Pharma</i>
March	<b>Migraine</b>	Merck, NeurAxon, Addex, others/ <i>Spotlight: Accera</i>
April	<b>Stroke</b>	Lundbeck, Paion, ReNeuron, others/ <i>Spotlight: Medivation</i>
May	<b>Pain</b>	Neuromed, Merck, Zogenix, others/ <i>Spotlight: NeuroNova</i>
June	<b>Epilepsy</b>	Valeant, Sepracor, Lundbeck, others/ <i>Spotlight: Marinus</i>
July-August	<b>Mid-year Review</b>	Preview of 2H:09 / <i>Spotlight: Seaside Therapeutics</i>
September	<b>Alzheimer's</b>	Elan, Lilly, EnVivo, Prana / <i>Spotlight: BrainCells</i>
October	<b>Parkinson's</b>	Acadia, Addex, Biovail / <i>Spotlight: Link Medicine</i>
November	<b>Depression</b>	BrainCells, Targacept, CeNeRx / <i>Spotlight: NeuroSearch</i>
December	<b>Neuroregeneration</b>	BrainCells, NeuroNova, more/ <i>Spotlight: StemCell Therapeutics</i>
<b>2008</b>		
January	<b>Review of 2007</b>	Preview of 2008/ <i>Spotlight: Evotec</i>
February	<b>ALS</b>	Sangamo, Cambria, others/ <i>Spotlight: Sangamo</i>
March	<b>Bipolar Disorder</b>	Lundbeck, Affectis, others/ <i>Spotlight: Intra-Cellular</i>
April	<b>Huntington's</b>	Medivation, Prestwick/ <i>Spotlight: Neurocrine Biosciences</i>
May	<b>Depression</b>	BrainCells, Lundbeck, Affectis, more/ <i>Spotlight: M's Science</i>
June	<b>Multiple Sclerosis</b>	Elan, Biogen-Idec, Bayhill, Active Biotech / <i>Spotlight: Vanda</i>
July-August	<b>Mid-year Review</b>	Preview of 2H:08 / <i>Spotlight: Avigen</i>
September	<b>Alzheimer's</b>	Elan, Wyeth, Acumen, Allon/ / <i>Spotlight: Allon Therapeutics</i>
October	<b>Neuropathic Pain</b>	Neuromed, Evotec, Trophos, Cervelo/ <i>Spotlight: Targacept</i>
November	<b>Addiction</b>	Catalyst, Titan, Yaupon, Synosia/ <i>Spotlight: Pfizer</i>
December	<b>Anxiety</b>	Pfizer, Lundbeck, Synosia, Addex/ <i>Spotlight: ALSP</i>

*\*in preparation*

**back issues:** Subscribers: \$200 per issue. Non-subscribers \$300 per issue (\$400 for Alzheimer's). Issues over twelve months old are not available

# Private CNS Company Review 2009: Table of Contents

*Introduction and Comment*

*Private Company Fates and Casualties 2003-8*

*Private CNS Company Licensing Opportunities*

*Top PCNS Licensing Opportunities*

*Top PCNS M&A Opportunities*

**Accera**

**AC Immune**

**Acumen Pharmaceuticals**

**Adamas Pharmaceuticals**

**Affectis Pharmaceuticals**

**Affiris**

**Alzhyne**

**American Life Science Pharmaceuticals**

**Archer Pharmaceuticals**

**Argolyn Biosciences**

**Arcion Therapeutics**

**Ariston Pharmaceuticals**

**ArmaGen Technologies**

**AurimMed Pharma**

**Avera Pharmaceuticals**

**Axon-Neuroscience**

**Axxonis Pharma AG**

**Azevan Pharmaceuticals**

**Bayhill Therapeutics**

**BioArctic Neuroscience**

**Biocortech**

**BrainCells**

**BrainTact**

**Brane Discovery**

**Cambria Bioscience**

**Cara Therapeutics**

**Cellzome**

**CeNeRx BioPharma**

**Genomed**

**Ceregene**

**Cervelo Pharma**

**Clera**

**Cognition Therapeutics**

**Cognosci**

**CoLucid**

**CoMentis**

**Conogenetix Biosciences**

**D-Pharm**

**Embera Neurotherapeutics**

**ENKAM Pharmaceuticals**

**EnVivo Pharmaceuticals**

**Faust Pharmaceuticals**

**Galantos Pharma**

**Galenea**

**Gemac Pharma**

**GliaMed**

**Helicon Therapeutics**

**Intra-Cellular Therapies**

**KeyNeurotek**

**Kinexis**

**Knopp Neurosciences**

**Link Medicine**

**Maas Biolab**

**Mapreg**

**Marinus Pharmaceuticals**

**Medeia Therapeutics**

**MediProPharma**

**Mithridion**

**M's Science**

**Neuraxo Biotec**

**Neuraxon**

**Neuréva**

**Neurim**

**Neurimmune**

**Neurion**

**NeuroHealing**

**NeuroKos**

**Neuromed Pharmaceuticals**

**Neuronascent**

**Neuronautics**

**NeuroNova**

**NeuroProtect**

**NeuroTherapeutics Pharma**

**Neurotune AG**

**NoNO Inc.**

**NsGene**

**NuPathe**

**Ovation Pharmaceuticals**

**PainCeptor**

**PharmaNeuroBoost**

**Pharmaxon**

**Pharnext**

**Probiodrug**

**Proneuron Biotechnologies**

**Psyadon Pharmaceuticals**

**Reata Pharmaceuticals**

**RemeGenix**

**SanBio**

**Sanomune**

**Seaside Therapeutics**

**Senexis**

**Sierra Neuropharmaceuticals**

**Solstice Neurosciences**

**Sonexa Therapeutics**

**Spinifex**

**Stealth Peptides**

**Synosia Therapeutics**

**TauRx**

**TheraQuest Biosciences**

**Thuris**

**Tikvah Therapeutics**

**Traxion Therapeutics**

**Trophos**

**Voyager Pharmaceuticals**

**Xenome Ltd**

**Xytis Pharmaceuticals**

**Yaupon Therapeutics**

**Zenobia**

**Zogenix**

*Programs by Company, Indication, Stage*

*Company Funding and VCs*

*VC Funding Roster*

## NI Research Publications

The just-released *Private CNS Company Review* for 2009 is a unique Business Development resource, which assesses the platform and prospects for privately-held CNS-oriented companies. It also evaluates partnering and M&A options amongst these companies. 112 companies. 149 pages.

**PCNS 2009:** US\$4000

**NeuroInvestment:** US\$1600 per year

**CNS 2008 Disorders/Therapeutics:** US\$5000  
(US\$3000 for small/early-stage companies)

A 15% discount for attendees of this GTCbio conference is offered through January 15, 2009.

Additional PCNS 2009 discounts for *NeuroInvestment* subscribers and purchasers of *CNS2008 Disorders/Therapeutics* are also available. Please contact us at [info@neuroinvestment.com](mailto:info@neuroinvestment.com), or call us at 760.753.6376